Biotechnology company Aicuris Anti-Infective Cures AG has announced its Phase III trial of pritelivir, a treatment for Herpes Simplex Virus (HSV), has reached its primary endpoint. The first-in-class helicase primase inhibitor met its primary endpoint of superiority (p=0.0047) in lesion healing in HSV patients receiving treatment up to 28 days. Statistical superiority… Read More
A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. The three-year survival rate for children with high-grade gliomas, without further complications, is only… Read More
A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of… Read More
